Singapore, June 5 -- Chime Biologics, a China-based biologics CDMO dedicated to enabling partners' success, and South Korea-based Daewoong Pharmaceutical, have announced the signing of a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent.

Through this partnership, Chime Biologics will leverage its extensive end-to-end biosimilar development and commercialisation experiences, advanced AI-enabled development platform (Chime AI Platform), and the rapidly evolving bioprocess supply chain ecosystem in China (Chime Innovation Alliance) to support Daewoong Pharmaceutical's global biosimilar ambitions.

The dupilumab biosimilar marks Daewoong Pharmaceutical's full-fledge...